Business Context and Reporting Period
This Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on August 7, 2026, reporting a significant legal settlement regarding its product DOJOLVI (triheptanoin) oral liquid.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal event rather than periodic financial performance.
Material Changes
The primary material change is the resolution of patent litigation with Esjay Pharma Private Limited and Esjay Pharma LLC (collectively "Esjay"). The litigation arose from Esjay's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of DOJOLVI.
Guidance, Outlook, and Management Commentary
- Settlement Terms: Ultragenyx granted Esjay a non-exclusive, royalty-free license to market a generic version of DOJOLVI.
- Effective Date: The license becomes effective on January 1, 2033.
- Contingency: The entry date may be extended to July 1, 2033, if pediatric exclusivity is granted for DOJOLVI.
- Regulatory Review: The agreement is subject to submission to the U.S. Federal Trade Commission and the U.S. Department of Justice.
- Pending Litigation: Similar patent litigation against other ANDA filers remains pending in the U.S. District Court for the District of New Jersey.
Investor Verification Checklist
- Verify the exact terms of the royalty-free license and any conditions or exceptions not detailed in the summary.
- Monitor the status of pediatric exclusivity for DOJOLVI to determine if the generic entry date shifts to July 1, 2033.
- Track the progress of pending patent litigation against other ANDA filers mentioned in the filing.
- Confirm the outcome of the regulatory review by the FTC and DOJ regarding the settlement agreement.